EMA Authorised: Ammonaps (sodium phenylbutyrate) — Immedica Pharma AB

View source ↗

Summary

EMA authorised Ammonaps (sodium phenylbutyrate) for OTCD, citrullinemia, and CPS1 deficiency conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carbamoyl-phosphate Synthase Deficiency Disease
• Citrullinemia
• Ornithine Carbamoyltransferase Deficiency Disease

Drugs mentioned

• Ammonaps (sodium phenylbutyrate)

Snippet

Status: Authorised. Therapeutic area: Ornithine Carbamoyltransferase Deficiency Disease;Citrullinemia;Carbamoyl-Phosphate Synthase I Deficiency Disease. MAH: Immedica Pharma AB. Decision date: 12/12/2022